**6. Conclusions**

The conventional approach to developing therapeutics for AD has been focused on the Aβ hypothesis, which insists that Aβ causes AD pathologies. However, this approach has yet to provide a successful treatment or prevention method for AD. Based on the metabolic alterations that occur in the pathological markers of AD, this review suggests that the adipocyte metabolite adiponectin can be considered a therapeutic option for the treatment of AD.

**Author Contributions:** J.E.L. provided concept, design, and overall supervision of this study. J.Y.K. and S.B. contributed to the writing and drawing. Y.J.J. participated in the discussion and revision. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by a grant from the National Research Foundation of Korea (NRF) through a grant funded by the Ministry of Science, ICT, and Future Planning (NRF-2017R1A2B2005350).

**Conflicts of Interest:** The authors declare no conflict of interest.

#### **References**


© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
